13 completed, 5 terminated, 3 recruiting, 2 active not recruiting. 27 Phase 1, 10 Phase 2.
Follow Disorders of Sex Development: new trials by email Literature Review of Disorders of Sex Development trials Research Report on Disorders of Sex Development
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620 OMS1620, Placebo - Congenital Adrenal Hyperplasia (CAH) | Phase 1 | Not yet recruiting | OMass Therapeutics Australia Proprietary Ltd | 84 | 2026-09-01 | 2026-09-09 |
| A Multiple Baseline Feasibility Trial of Social Management Training for People With Sex Chromosome Aneuploidies Social Management Training - Sex Chromosome Disorders | Phase 1 | Recruiting | University of Oslo | 30 | 2026-06-01 | 2026-07-22 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718 - Hypothalamic Obesity, Prader-Willi Syndrome | Phase 1 / Phase 2 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 111 | 2024-03-05 | 2026-10-09 |
| A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia Lu AG13909 - Congenital Adrenal Hyperplasia | Phase 1 / Phase 2 | Recruiting | H. Lundbeck A/S | 42 | 2022-12-19 | 2026-03-09 |
| A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) AAV BBP-631 - Congenital Adrenal Hyperplasia | Phase 1 / Phase 2 | Active not recruiting | Adrenas Therapeutics Inc | 8 | 2021-07-01 | 2025-12-23 |
| Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia Subcutaneous hydrocortisone - Congenital Adrenal Hyperplasia, Hyperplasia | Phase 1 | Completed | University of Minnesota | 11 | 2019-01-01 | 2025-06-25 |
| Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism TAB METFORMIN, TAB PIOGLITAZONE - Menstrual Irregularities, Hyperandrogenism | Phase 1 / Phase 2 | Unknown | Dow University of Health Sciences | 110 | 2018-06-18 | 2018-11-29 |
| Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 Abiraterone acetate - Congenital Adrenal Hyperplasia | Phase 1 | Terminated | University of Texas Southwestern Medical Center | 4 | 2017-08-01 | 2025-11-04 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia NBI-77860 - Congenital Adrenal Hyperplasia | Phase 1 | Withdrawn | Neurocrine Biosciences | 2015-02-01 | 2015-06-11 | |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer Ganetespib, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Medical University Innsbruck | 133 | 2014-07-04 | 2019-08-13 |
| Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia Solu-Cortef, Cortef - Addison Disease, Adrenal Hyperplasia Congenital | Phase 1 / Phase 2 | Completed | Haukeland University Hospital | 8 | 2014-03-27 | 2024-06-07 |
| Kisspeptin in the Evaluation of Delayed Puberty kisspeptin 112-121, GnRH - Delayed Puberty, Kallmann Syndrome | Phase 1 | Completed | Massachusetts General Hospital | 24 | 2013-06-08 | 2023-10-19 |
| Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Salsalate - Polycystic Ovary Syndrome | Phase 1 | Terminated | Indiana University | 47 | 2012-02-01 | 2017-02-10 |
| Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling kisspeptin 112-121, GnRH - Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women | Phase 1 | Completed | Massachusetts General Hospital | 96 | 2011-09-01 | 2022-07-11 |
| Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone Progesterone, Placebo - Polycystic Ovary Syndrome, Hyperandrogenism | Phase 1 | Unknown | University of Virginia | 40 | 2011-03-11 | 2023-11-02 |
| A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations Chronocort - Adrenal Insufficiency, Congenital Adrenal Hyperplasia | Phase 1 | Completed | Neurocrine UK Limited | 28 | 2011-02-01 | 2026-09-14 |
| Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH) Anastrozole Pill, Testosterone, Placebo Oral Tablet - Hypogonadotropic Hypogonadism, Kallmann Syndrome | Phase 1 | Terminated | Massachusetts General Hospital | 7 | 2010-05-01 | 2017-04-18 |
| An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone Hydrocortisone, Chronocort - Congenital Adrenal Hyperplasia, Adrenal Insufficiency | Phase 1 | Completed | Neurocrine UK Limited | 30 | 2010-03-01 | 2026-09-14 |
Showing 20 of 27. Sign in to see all of them.
Adrenal Hyperplasia, Congenital (11) · Hypogonadism (5) · Kallmann Syndrome (5) · Hyperandrogenism (3) · Polycystic Ovary Syndrome (3) · Adrenal Gland Diseases (2) · Adrenal Insufficiency (2) · Adrenocortical Hyperfunction (2) · Adrenogenital Syndrome (2) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (2) · Dermatofibrosarcoma (2) · Fibrosarcoma (2) · Genetic Diseases, Inborn (2) · Hemangiosarcoma (2)
Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Male Urogenital Diseases (27) · Urogenital Diseases (27) · Congenital Abnormalities (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Endocrine System Diseases (26) · Gonadal Disorders (26) · Urogenital Abnormalities (25) · Genetic Diseases, Inborn (17) · Nutritional and Metabolic Diseases (13) · Adrenogenital Syndrome (12) · Metabolic Diseases (11) · Metabolism, Inborn Errors (10)
Gonadotropin-Releasing Hormone (5) · Hydrocortisone (3) · Doxorubicin (2) · Abiraterone Acetate (1) · Anastrozole (1) · Estradiol (1) · Exenatide (1) · Human Growth Hormone (1) · Ifosfamide (1) · Metformin (1) · NBI 77860 (1) · Nifedipine (1) · Paclitaxel (1) · Pioglitazone (1) · Progesterone (1)
Massachusetts General Hospital (6) · Neurocrine UK Limited (3) · Adrenas Therapeutics Inc (1) · Children's Hospitals and Clinics of Minnesota (1) · Dow University of Health Sciences (1) · H. Lundbeck A/S (1) · Haukeland University Hospital (1) · Indiana University (1) · Medical University Innsbruck (1) · National Center for Research Resources (NCRR) (1) · Neurocrine Biosciences (1) · OHSU Knight Cancer Institute (1) · OMass Therapeutics Australia Proprietary Ltd (1) · Rhythm Pharmaceuticals, Inc. (1) · St. Jude Children's Research Hospital (1)
United States (20) · France (2) · Norway (2) · Austria (1) · Belgium (1) · Denmark (1) · Georgia (1) · Germany (1) · Ireland (1) · Italy (1) · Pakistan (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Stephanie B Seminara, MD (4) · Bader F Zuberi, FCPS (1) · Christopher R McCartney, MD (1) · David Meeker (1) · Girish Sharma (1) · Jessica Gartrell, MD (1) · Katerina Simunkova, MD, PhD (1) · Kyriaki Sarafoglou, MD (1) · Lara E Davis (1) · M. Jennifer Abuzzahab, MD (1) · Nelly Pitteloud, MD (1)
PMID 11788640, PMID 12213860, PMID 17761590, PMID 19829004, PMID 20382682, PMID 21209029, PMID 2122732, PMID 2502554, PMID 25226293, PMID 28368443, PMID 29669934, PMID 30590569, PMID 3096182, PMID 3098771, PMID 31132118, PMID 32034419, PMID 32140727, PMID 32232399, PMID 32325487, PMID 33278125, PMID 37172949, PMID 3900124, PMID 39965102, PMID 41273106, PMID 42230485, PMID 6767977, PMID 6813732, PMID 9010147, PMID 9174769, PMID 9922906
U54HD028138 (2), M01RR001070 (1), P50HD028934 (1), U01HD083493 (1)